OPEN LABELLED PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF DENOSUMAB ON OSTEOPOROSIS IN KIDNEY TRANSPLANT RECIPIENT

IPGMER AND SSKM HOSPITAL KOLKATA0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1. All the renal transplant recipients transplanted in our institute with less than 1 year from the date of renal transplant to study entry point.
•2.Age older than 18 years.
•3. DEXA SCAN T Score less than -2.5 i.e. suggestive of osteoporosis.

•1. eGFR < 30 ml/min/1.73m2
•2. Patients after total parathyroidectomy and Evidence of severe hyper- or hypo-parathyroidism i.e.(iPTH >800 ng/l or <10 ng/l)
•3. Patients treated with bisphosphonates, fluoride, calcitonin, or anabolic steroids with in 1 years of enrolment.
•4. Hypocalcemia (total calcium <1.8 mmol/l or 7.2 mg/dl) or hypercalcemia (total calcium >2.7 mmol/l or 10.8 mg/dl)
•(Patients will be included in the study after correcting the hypo or hypercalcemia.)
•5. Active infections and/or malignancy.
•6. Ongoing pregnancy.

发起方

IPGMER AND SSKM HOSPITAL KOLKATA